Biotech workers

Download The Article

A 2023 Toolkit for Emerging Biotech

A 2023 Toolkit for Emerging Biotech

Practical Advice for Navigating Challenges
& Advancing Clinical Development

In a competitive landscape where resources are limited, emerging biotechs must define and adhere to a strategy early on to successfully take their compound through development to commercialization. 

In a newly released article, a Toolkit for Emerging Biotechs: Practical Advice for Navigating Challenges & Advancing Clinical Development, Medpace experts share key strategies to overcome common biotech challenges.

cells rendering
An Integrated Partner for Biotech

trusted by biotech

There’s a reason 90% of our clients are small to mid-sized biotechs. While Medpace has grown over the last 30 years, the way we work with biotechs has not changed:

  • We remain committed to being Trusted by Biotech®, which translates to keeping our culture and operating structure designed to accommodate efficient partnering, which is crucial for emerging biotechs with limited resources or experience
  • Our purposeful, organic growth provides consistency in leadership, deep institution experience, and incomparable efficiencies, allowing your compound the attention it deserves
  • We continue to expand our global reach and therapeutic expertise, providing resources to advance your medical therapeutic in any region.

Biotechs need a CRO that will give their program the attention it deserves. Medpace has prioritized biotechs for over three decades; we draw on our experience to create the best team and solution for you because at Medpace, we share the same commitment to your compound that you do.